Keyphrases
Type 2 Diabetes Mellitus (T2DM)
69%
Type 2 Diabetic Patients
62%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
56%
Heart Failure
46%
Metformin
45%
Left Ventricular Hypertrophy
45%
Cardiovascular Effects
39%
Loop Diuretics
32%
Without Diabetes
31%
Placebo
30%
Patients with Heart Failure
30%
Patients with Coronary Artery Disease
30%
Dapagliflozin
30%
Renal Effects
30%
Coronary Artery Disease
24%
Patients with Diabetes
24%
Cotransporter
24%
Empagliflozin
24%
Regress
21%
Randomized Controlled Trial
20%
Cardiac Magnetic Resonance Imaging (cMRI)
19%
Left Ventricular Mass
19%
Diabetes
18%
Meta-analysis
18%
Heart Failure with Preserved Ejection Fraction (HFpEF)
17%
Aortic Valve Stenosis
15%
CV Events
15%
Pooled Cohort Equations
15%
Left Ventricular Remodeling
15%
KLF15
15%
Sodium-glucose Cotransporter
15%
Epicardial Adipose Tissue
15%
Sweet
15%
Glucose-lowering Drugs
15%
Glucose Metabolic
15%
Metabolic Effects
15%
Diabetic Patients
15%
Metabolic Traits
15%
Clinical Data
15%
Genomic Data
15%
Mendelian Randomization
15%
LV Hypertrophy
15%
Genetic Variation
15%
Chronic Heart Failure
15%
Patients with Chronic Heart Failure
15%
Population Cohort Study
15%
Disease-associated
15%
Major Adverse Cardiovascular Events
15%
Microvascular Disease
15%
9p21 Locus
15%
Systematic Meta-analysis
15%
Metabolic Risk Factors
15%
Randomized Placebo-controlled Trial
15%
Scotland
13%
Insulin Resistance
13%
Tayside
10%
Heart Failure Hospitalization
10%
Cardioprotection
9%
Single nucleotide Polymorphism
9%
Sodium
9%
Type II Inhibitor
9%
Hemoglobin A1c (HbA1c)
8%
Incident Heart Failure
8%
Urine Volume
8%
Hazard Ratio
8%
Diabetes Genetics
7%
Metformin Use
7%
GLP-1 Receptor Agonist
7%
Cardiovascular Disease
7%
Retinal Photographs
7%
Fractal Dimension
7%
Cardiovascular Risk Assessment
7%
Vascular Parameters
7%
Vascular Assessment
7%
Retinal Vascular Network
7%
Risk Score
7%
Area under the Curve
7%
Confidence Interval
7%
Diuretics
7%
Cardiovascular Outcome Trials
6%
Cardiovascular Outcomes
6%
Cardiovascular Risk
6%
Fasting Insulin
6%
Glycated Hemoglobin
6%
Systolic Blood Pressure
6%
Oxidative Stress
6%
Metformin Treatment
6%
Pre-diabetes (pre-DM)
6%
EMPA-REG
6%
Oral Hypoglycemic Agents
6%
Magnetic Resonance Imaging
6%
Sensitivity Analysis
5%
Genetic Liability
5%
High Risk
5%
Pleiotropy
5%
Absolute Benefit
5%
Odds Ratio
5%
Urinary Sodium Excretion
5%
Once-daily
5%
Placebo-controlled
5%
Randomized Double-blind
5%
Medicine and Dentistry
Congestive Heart Failure
84%
Patient with Type 2 Diabetes
60%
Maturity Onset Diabetes of the Young
56%
Diabetes
50%
Glycon
45%
Left Ventricular Hypertrophy
45%
Coronary Artery Disease
31%
Loop Diuretic Agent
30%
Cardiovascular Effect
30%
Sodium Glucose Cotransporter 2 Inhibitor
26%
Cotransporter
24%
Placebo
23%
Empagliflozin
22%
Cardiovascular Disease
21%
Randomized Controlled Trial
19%
Cardiovascular Risk
18%
Cardiovascular System
17%
Adipose Tissue
17%
Heart Failure with Reduced Ejection Fraction
17%
Cardiac Magnetic Resonance Imaging
15%
Systematic Review
15%
Placebo-Controlled Study
15%
Meta-Analysis
15%
Microangiopathy
15%
Heart Failure with Preserved Ejection Fraction
15%
Kruppel Like Factor
15%
Sodium Glucose Cotransporter 2
15%
Mendelian Randomization Analysis
15%
Cohort Analysis
15%
Dapagliflozin
15%
Genetic Variation
15%
Diabetes Mellitus
15%
Urinary System
13%
Insulin Resistance
13%
Photograph
11%
Allele
10%
Single Nucleotide Polymorphism
10%
Patient with Diabetes
9%
Genetics of Diabetes
7%
Hazard Ratio
7%
Diuretic Agent
6%
Body Weight
6%
Oral Antidiabetic Agent
6%
Clinical Trial
5%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
5%
Glycated Hemoglobin
5%
Magnetic Resonance Imaging
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Congestive Heart Failure
91%
Metformin
45%
Heart Left Ventricle Hypertrophy
45%
Sodium Glucose Cotransporter 2 Inhibitor
41%
Placebo
38%
Loop Diuretic Agent
32%
Coronary Artery Disease
30%
Dapagliflozin
30%
Cotransporter
24%
Cardiovascular Disease
22%
Empagliflozin
22%
Randomized Controlled Trial
19%
Cardiovascular Risk
18%
Heart Failure with Reduced Ejection Fraction
17%
Cohort Study
15%
Heart Failure with Preserved Ejection Fraction
15%
Placebo-Controlled Study
15%
Kruppel Like Factor
15%
Sodium Glucose Cotransporter 2
15%
Heart Ventricle Remodeling
15%
Microangiopathy
15%
Diabetes Mellitus
15%
Diuretic Agent
6%
Insulin Resistance
6%
Oral Antidiabetic Agent
6%
Clinical Trial
5%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
5%